Quote | Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)
Last: | $21.49 |
---|---|
Change Percent: | -0.09% |
Open: | $21.5 |
Close: | $21.51 |
High: | $21.55 |
Low: | $21.45 |
Volume: | 188,580 |
Last Trade Date Time: | 05/20/2024 03:00:00 am |
News | Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)
2024-05-19 14:00:55 ET More on pharma companies Novo Nordisk, J&J lead R&D rankings in big pharma: report Shockwave Medical: A Look Into Q1 Financials And Value To Johnson & Johnson Investors Johnson & Johnson: Buy This Bargain Before It's Gone ...
Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer Canada NewsWire AlphaBreak is a Phase 2/3 registrational program for FPI-2265 in patients with metastati...
Message Board Posts | Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $FUSN News Article - Fusion Pharmaceuticals Announces IND Clearance for FPI-2068, a Joi | whytestocks | investorshangout | 04/12/2023 8:15:45 PM |
znewcar1: $SKYT 22% v3,0M C13.98 f43,285M H15.33 ML2.93 | znewcar1 | investorshangout | 02/14/2023 10:59:56 PM |
whytestocks: $FUSN News Article - Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I | whytestocks | investorshangout | 02/13/2023 9:15:48 PM |
whytestocks: $FUSN News Article - Fusion Pharmaceuticals Reports Progress and Provides Recent Corpor | whytestocks | investorshangout | 01/06/2023 6:55:52 PM |
whytestocks: $FUSN News Article - Fusion Pharmaceuticals Announces Third Quarter 2022 Financial Resu | whytestocks | investorshangout | 11/08/2022 3:35:50 PM |
News, Short Squeeze, Breakout and More Instantly...
Fusion Pharmaceuticals Inc. Company Name:
FUSN Stock Symbol:
NASDAQ Market:
NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the ...
Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer Canada NewsWire AlphaBreak is a Phase 2/3 registrational program for FPI-2265 in patients with metastati...
Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates Canada NewsWire Presented interim data from TATCIST trial of FPI-2265 in mCRPC at the 2024 American Association for Cancer Research (AACR) Annual Meeting Si...